• Savara highlighted Phase 3 IMPALA-2 data for MOLBREEVI (molgramostim inhalation solution) in autoimmune pulmonary alveolar proteinosis, showing a statistically significant improvement in the primary endpoint of change in DLCO% at Week 24 versus placebo (p=0.0007).
• DLCO% gains were sustained at Week 48, with a statistically significant between-group difference versus placebo (p=0.0008).
• Patient-reported outcomes improved at Week 24, with a statistically significant reduction in SGRQ Total Score versus placebo (p=0.0072), while Week 48 did not reach statistical significance (p=0.1046).
• The presentation set an FDA BLA PDUFA date of Nov. 22, 2026 for MOLBREEVI, which remains unapproved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.